These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37667412)

  • 41. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuropathological correlates of neuropsychiatric symptoms in dementia.
    Gibson LL; Grinberg LT; Ffytche D; Leite REP; Rodriguez RD; Ferretti-Rebustini REL; Pasqualucci CA; Nitrini R; Jacob-Filho W; Aarsland D; Suemoto CK
    Alzheimers Dement; 2023 Apr; 19(4):1372-1382. PubMed ID: 36150075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cerebral amyloid angiopathy in Lewy body disease.
    Jellinger KA; Attems J
    J Neural Transm (Vienna); 2008; 115(3):473-82. PubMed ID: 18301958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease.
    Schaffert J; LoBue C; White CL; Wilmoth K; Didehbani N; Lacritz L; Nguyen T; Peters ME; Fields L; Li C; Cullum CM
    Alzheimers Dement; 2020 Mar; 16(3):524-530. PubMed ID: 32043803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer's dementias.
    Michno W; Koutarapu S; Camacho R; Toomey C; Stringer K; Minta K; Ge J; Jha D; Fernandez-Rodriguez J; Brinkmalm G; Zetterberg H; Blennow K; Ryan NS; Lashley T; Hanrieder J
    J Neurochem; 2022 Nov; 163(3):233-246. PubMed ID: 36102248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathologically Confirmed Cerebral Amyloid Angiopathy with No Radiological Sign in a Patient with Early Onset Alzheimer's Disease.
    Kim SJ; Seo Y; Kim HJ; Na DL; Seo SW; Kim Y; Suh YL
    Yonsei Med J; 2018 Aug; 59(6):801-805. PubMed ID: 29978619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders.
    Coughlin DG; Phillips JS; Roll E; Peterson C; Lobrovich R; Rascovsky K; Ungrady M; Wolk DA; Das S; Weintraub D; Lee EB; Trojanowski JQ; Shaw LM; Vaishnavi S; Siderowf A; Nasrallah IM; Irwin DJ; McMillan CT;
    Neurobiol Aging; 2020 Dec; 96():137-147. PubMed ID: 33002767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tau pathology associates with in vivo cortical thinning in Lewy body disorders.
    Spotorno N; Coughlin DG; Olm CA; Wolk D; Vaishnavi SN; Shaw LM; Dahodwala N; Morley JF; Duda JE; Deik AF; Spindler MA; Chen-Plotkin A; Lee EB; Trojanowski JQ; McMillan CT; Weintraub D; Grossman M; Irwin DJ
    Ann Clin Transl Neurol; 2020 Dec; 7(12):2342-2355. PubMed ID: 33108692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
    Geng C; Tan L; Chen C
    Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates.
    De Reuck J; Deramecourt V; Auger F; Durieux N; Cordonnier C; Devos D; Defebvre L; Moreau C; Caparros-Lefebvre D; Bordet R; Maurage CA; Pasquier F; Leys D
    J Neurol Sci; 2014 Nov; 346(1-2):85-9. PubMed ID: 25129206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease.
    Buciuc M; Whitwell JL; Boeve BF; Ferman TJ; Graff-Radford J; Savica R; Kantarci K; Fields JA; Knopman DS; Petersen RC; Parisi JE; Murray ME; Dickson DW; Josephs KA
    J Neurol; 2020 May; 267(5):1444-1453. PubMed ID: 32006160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imaging features of small vessel disease in cerebral amyloid angiopathy among patients with Alzheimer's disease.
    Nagaraja N; DeKosky S; Duara R; Kong L; Wang WE; Vaillancourt D; Albayram M
    Neuroimage Clin; 2023; 38():103437. PubMed ID: 37245492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline.
    Rabin JS; Nichols E; La Joie R; Casaletto KB; Palta P; Dams-O'Connor K; Kumar RG; George KM; Satizabal CL; Schneider JA; Pa J; Brickman AM
    Brain; 2022 Aug; 145(8):2823-2833. PubMed ID: 35759327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Expression of proteins related neurodegeneration in autopsy brains of the aged].
    Zhu M; Meng X; Wang L; Hu Y; Zhang H; Han Z
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):651-6. PubMed ID: 25567589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer's disease.
    Coughlin DG; Ittyerah R; Peterson C; Phillips JS; Miller S; Rascovsky K; Weintraub D; Siderowf AD; Duda JE; Hurtig HI; Wolk DA; McMillan CT; Yushkevich PA; Grossman M; Lee EB; Trojanowski JQ; Irwin DJ
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):707-721. PubMed ID: 32892355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neurodegenerative pathologies associated with behavioral and psychological symptoms of dementia in a community-based autopsy cohort.
    Nelson RS; Abner EL; Jicha GA; Schmitt FA; Di J; Wilcock DM; Barber JM; Van Eldik LJ; Katsumata Y; Fardo DW; Nelson PT
    Acta Neuropathol Commun; 2023 Jun; 11(1):89. PubMed ID: 37269007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update.
    Perrin RJ; Franklin EE; Bernhardt H; Burns A; Schwetye KE; Cairns NJ; Baxter M; Weiner MW; Morris JC;
    Alzheimers Dement; 2024 Nov; 20(11):7859-7870. PubMed ID: 39351959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.